UPDATED Feb 18, 2024
Defensive mid-caps and large-caps in descending order of expected ROE in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
AMGNAmgen | US$283.70 | -2.5% | 17.9% | US$152.0b | US$303.65 | PE22.6x | E9.2% | 3.2% | ||
ABBVAbbVie | US$177.49 | 2.0% | 17.3% | US$313.4b | US$178.42 | PE64.4x | E23.1% | 3.5% | ||
OGNOrganon | US$18.71 | 14.2% | -28.1% | US$4.8b | US$21.11 | PE4.7x | E-5.0% | 6.0% | ||
MRKMerck | US$127.79 | 1.9% | 16.7% | US$323.8b | US$133.26 | PE887.2x | E24.7% | 2.4% | ||
BMYBristol-Myers Squibb | US$49.86 | 0.1% | -29.9% | US$100.8b | US$58.15 | PE12.6x | E7.6% | 4.8% | ||
JNJJohnson & Johnson | US$156.55 | -0.8% | -2.4% | US$377.1b | US$174.55 | PE28.3x | E9.3% | 3.0% | ||
GILDGilead Sciences | US$71.58 | -2.8% | -15.5% | US$89.2b | US$88.01 | PE15.7x | E6.7% | 4.3% | ||
RPRXRoyalty Pharma | US$29.92 | 2.3% | -20.9% | US$17.9b | US$45.44 | PE11.8x | E5.9% | 2.8% | ||
PFEPfizer | US$27.62 | 0.2% | -36.1% | US$156.0b | US$33.00 | PE73.1x | E19.1% | 6.1% | ||
VTRSViatris | US$13.06 | 11.8% | 11.7% | US$15.7b | US$11.73 | PE8.6x | E-10.5% | 3.7% | ||
PRGOPerrigo | US$32.03 | 0.5% | -12.0% | US$4.3b | US$44.75 | PE409.5x | E45.2% | 3.4% |